Cancer combo trial ends early – only one patient joined
Disease control
Terminated
This study tested a combination of two drugs (regorafenib and pembrolizumab) for people with a specific type of advanced colorectal cancer called MSI-H. The goal was to see if the combination worked better than pembrolizumab alone. However, the trial was stopped early after only …
Phase: PHASE2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated May 17, 2026 02:02 UTC